LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 141

Search options

  1. Article ; Online: Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.

    Toda, Soji / Hiroshima, Yukihiko / Iwasaki, Hiroyuki / Masudo, Katsuhiko

    The Journal of clinical endocrinology and metabolism

    2024  

    Abstract: Context: The relationship between genomic profile and prognosis of advanced thyroid carcinoma requiring drug therapy has not been reported.: Objective: To evaluate the treatment period and overall survival time for each genetic alteration in advanced ...

    Abstract Context: The relationship between genomic profile and prognosis of advanced thyroid carcinoma requiring drug therapy has not been reported.
    Objective: To evaluate the treatment period and overall survival time for each genetic alteration in advanced thyroid carcinoma that requires drug therapy.
    Methods: We conducted a retrospective observational study using a national database in Japan, which included 552 cases of thyroid carcinoma out of 53,543 patients in the database.
    Results: The database included anaplastic thyroid carcinoma (23.6%), poorly differentiated thyroid carcinoma (10.0%), and differentiated thyroid carcinoma (66.4%). The most common genetic abnormalities were TERT promoter (66.3%), BRAF (56.7%), and TP53 (32.2%). The typical driver genes were BRAF V600E (55.0%), RAS (18.5%), RET fusion (4.7%), NTRK fusion (1.6%), and ALK fusion (0.4%). The most common regimen was lenvatinib, and the time to treatment failure was not different despite the presence of BRAF or RAS mutations. In differentiated thyroid carcinoma and poorly differentiated thyroid carcinoma, TP53 alterations independently predicted worse overall survival (hazard ratio = 2.205, 95% confidence interval: 1.135-4.283). In anaplastic thyroid carcinoma, no genetic alterations were associated with overall survival.
    Conclusion: Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.
    Language English
    Publishing date 2024-04-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgae271
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.134: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.

    Toda, Soji / Iwasaki, Hiroyuki / Okubo, Yoichiro / Hayashi, Hiroyuki / Kadoya, Mei / Takahashi, Hiroyuki / Yokose, Tomoyuki / Hiroshima, Yukihiko / Masudo, Katsuhiko

    Endocrine journal

    2023  Volume 71, Issue 1, Page(s) 31–37

    Abstract: We analyzed the outcomes of genetic testing to study the frequency of mutations in advanced thyroid cancer in Japan. Patients (n = 96) with unresectable or metastatic thyroid carcinoma were included for retrospective chart review. Results of gene panel ... ...

    Abstract We analyzed the outcomes of genetic testing to study the frequency of mutations in advanced thyroid cancer in Japan. Patients (n = 96) with unresectable or metastatic thyroid carcinoma were included for retrospective chart review. Results of gene panel testing, which was performed between May 2020 and April 2023, were analyzed. The median age of the patients was 73.5 years (range, 17-88); 59 were women, and 39 were men. Overall, 17 patients had anaplastic thyroid carcinoma (ATC), 68 had papillary thyroid carcinoma (PTC), 7 had follicular thyroid carcinoma, and 6 had poorly differentiated thyroid carcinoma (PDTC). Of the 81 patients with differentiated thyroid carcinoma (DTC) and PDTC, 88.9% were radioactive iodine-refractory, and 32.7% of all cases had previously been treated with multiple kinase inhibitors. Of ATC cases, 52.9% had BRAF mutations, and 5.9% had RET fusion. Of PTC cases, 83.1% had BRAF mutations, 9.2% had RET fusion, and 1.5% had NTRK fusion. One case each of ATC and PTC had a tumor mutation burden of ≥10. ATC cases had a significantly higher prevalence of TP53 alterations than the other cases (82.3% vs. 11.8%), whereas the frequencies of TERT promoter mutations were 88.2% in ATC cases and 64.7% in the other cases, albeit without a significant difference. In conclusion, 58.8% of ATC, 93.8% of PTC, and 42.9% of PDTC had genetic alterations linked to therapeutic agents. Active gene panel testing is required to increase treatment options.
    MeSH term(s) Male ; Humans ; Female ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Thyroid Neoplasms/genetics ; Thyroid Neoplasms/pathology ; Proto-Oncogene Proteins B-raf/genetics ; Retrospective Studies ; Iodine Radioisotopes ; Japan/epidemiology ; Thyroid Carcinoma, Anaplastic ; Thyroid Cancer, Papillary/genetics ; Adenocarcinoma ; Mutation ; Proline/analogs & derivatives ; Thiocarbamates
    Chemical Substances Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Iodine Radioisotopes ; prolinedithiocarbamate (135467-92-4) ; Proline (9DLQ4CIU6V) ; Thiocarbamates
    Language English
    Publishing date 2023-12-01
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 1151918-6
    ISSN 1348-4540 ; 0918-8959
    ISSN (online) 1348-4540
    ISSN 0918-8959
    DOI 10.1507/endocrj.EJ23-0342
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.207: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Clinical Significance of Tryptophanyl-tRNA Synthetase 1 Gene Expression in Patients With Locally Advanced Gastric Cancer.

    Oshima, Takashi / Hashimoto, Itaru / Hiroshima, Yukihiko / Kimura, Yayoi / Tanabe, Mie / Onuma, Shizune / Morita, Junya / Nagasawa, Shinsuke / Kanematsu, Kyohei / Aoyama, Toru / Yamada, Takanobu / Ogata, Takashi / Rino, Yasushi / Saito, Aya / Miyagi, Yohei

    Anticancer research

    2024  Volume 44, Issue 2, Page(s) 673–678

    Abstract: Background/aim: The tryptophanyl-tRNA synthetase 1 gene (WARS1), encodes a tryptophan-tRNA synthetase involved in the amino acidification of tryptophan-tRNA and has been reported to be involved in cancer cell growth, metastasis promotion, and drug ... ...

    Abstract Background/aim: The tryptophanyl-tRNA synthetase 1 gene (WARS1), encodes a tryptophan-tRNA synthetase involved in the amino acidification of tryptophan-tRNA and has been reported to be involved in cancer cell growth, metastasis promotion, and drug resistance in a variety of cancers. This study investigated the clinical significance of WARS1 expression as a biomarker in gastric cancer tissues obtained from patients with locally advanced gastric cancer (GC) who underwent radical resection.
    Patients and methods: WARS1 expression in GC tissues and adjacent normal gastric mucosa of 253 patients with pStage II/III GC who underwent curative resection was determined using quantitative polymerase chain reaction (PCR). Association of WARS1 expression levels, categorized into high and low expression based on the median expression levels, with clinicopathological factors and overall survival (OS) of these patients was assessed.
    Results: The low-WARS1 expression group had significantly higher serosal invasion, lymph node metastasis, lymphatic invasion, venous invasion, and pathological stage than did the high-WARS1 expression group. OS was significantly worse in the low- than in the high-WARS1 expression group (5-year survival 52.2% vs. 75.9%; p=0.0001). Furthermore, in multivariate analysis, low WARS1 expression was an independent predictor for poor OS (hazard ratio=2.101; 95% confidence interval=1.328-3.322; p=0.002).
    Conclusion: In patients with locally advanced GC, after curative resection, WARS1 expression in GC tissue may be a useful prognostic marker.
    MeSH term(s) Humans ; Stomach Neoplasms/genetics ; Stomach Neoplasms/surgery ; Stomach Neoplasms/pathology ; Tryptophan-tRNA Ligase/genetics ; Clinical Relevance ; Tryptophan ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/analysis ; Gene Expression ; Prognosis ; Neoplasm Staging
    Chemical Substances Tryptophan-tRNA Ligase (EC 6.1.1.2) ; Tryptophan (8DUH1N11BX) ; Biomarkers, Tumor
    Language English
    Publishing date 2024-02-02
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.16857
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Evaluation of pancreatic cancer specimens for comprehensive genomic profiling.

    Washimi, Kota / Hiroshima, Yukihiko / Sato, Shinya / Ueno, Makoto / Kobayashi, Satoshi / Yamamoto, Naoto / Hasegawa, Chie / Yoshioka, Emi / Ono, Kyoko / Okubo, Yoichiro / Yokose, Tomoyuki / Miyagi, Yohei

    Pathology international

    2024  

    Abstract: Inadequate specimen quality or quantity hinders comprehensive genomic profiling in identifying actionable mutations and guiding treatment strategies. We investigated the optimal conditions for pancreatic cancer specimen selection for comprehensive ... ...

    Abstract Inadequate specimen quality or quantity hinders comprehensive genomic profiling in identifying actionable mutations and guiding treatment strategies. We investigated the optimal conditions for pancreatic cancer specimen selection for comprehensive genomic profiling. We retrospectively analyzed 213 pancreatic cancer cases ordered for comprehensive genomic profiling and compared results from pancreatic biopsy, liver biopsy of pancreatic cancer metastases, pancreatectomy, liquid, and nonliver metastatic organ specimens. We examined preanalytical conditions, including cellularity (tumor cell count/size). The successfully tested cases were those that underwent comprehensive genomic profiling tests without any issues. The successfully tested case ratio was 72.8%. Pancreatic biopsy had the highest successfully tested case ratio (87%), with a high tumor cell percentage, despite the small number of cells (median, 3425). Pancreatic biopsy, liver biopsy of pancreatic cancer metastases, and non-liver metastatic organ had higher successfully tested case ratios than that for pancreatectomy. Liver biopsy of pancreatic cancer metastases and pancreatectomy cases with tumor size (mm
    Language English
    Publishing date 2024-03-13
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 1194850-4
    ISSN 1440-1827 ; 1320-5463
    ISSN (online) 1440-1827
    ISSN 1320-5463
    DOI 10.1111/pin.13416
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.200: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.

    Kobayashi, Noritoshi / Takeda, Yuma / Okubo, Naoki / Suzuki, Akihiro / Tokuhisa, Motohiko / Hiroshima, Yukihiko / Ichikawa, Yasushi

    Cancer science

    2021  Volume 112, Issue 5, Page(s) 1936–1942

    Abstract: Extrapulmonary neuroendocrine carcinoma (EPNEC) is a lethal disease with a poor prognosis. Platinum-based chemotherapy is used as the standard first-line treatment for unresectable EPNEC. Several retrospective studies have reported the results of the ... ...

    Abstract Extrapulmonary neuroendocrine carcinoma (EPNEC) is a lethal disease with a poor prognosis. Platinum-based chemotherapy is used as the standard first-line treatment for unresectable EPNEC. Several retrospective studies have reported the results of the utilization of temozolomide (TMZ) as a drug for the second-line treatment for EPNEC. Patients with unresectable EPNEC that were resistant to platinum-based combination chemotherapy were recruited for a prospective phase II study of TMZ monotherapy. A 200 mg/m
    MeSH term(s) Adult ; Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Neuroendocrine/drug therapy ; Carcinoma, Neuroendocrine/enzymology ; Carcinoma, Neuroendocrine/mortality ; Carcinoma, Neuroendocrine/pathology ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/enzymology ; Colonic Neoplasms/pathology ; Drug Administration Schedule ; Duodenal Neoplasms/drug therapy ; Duodenal Neoplasms/enzymology ; Duodenal Neoplasms/pathology ; Female ; Gallbladder Neoplasms/drug therapy ; Gallbladder Neoplasms/enzymology ; Gallbladder Neoplasms/pathology ; Humans ; Ki-67 Antigen/analysis ; Liver Neoplasms/drug therapy ; Liver Neoplasms/enzymology ; Liver Neoplasms/pathology ; Male ; Middle Aged ; O(6)-Methylguanine-DNA Methyltransferase/analysis ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/enzymology ; Pancreatic Neoplasms/pathology ; Progression-Free Survival ; Prospective Studies ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/enzymology ; Stomach Neoplasms/pathology ; Temozolomide/administration & dosage ; Temozolomide/adverse effects ; Temozolomide/therapeutic use ; Uterine Neoplasms/drug therapy ; Uterine Neoplasms/enzymology ; Uterine Neoplasms/pathology
    Chemical Substances Antineoplastic Agents, Alkylating ; Ki-67 Antigen ; O(6)-Methylguanine-DNA Methyltransferase (EC 2.1.1.63) ; Temozolomide (YF1K15M17Y)
    Language English
    Publishing date 2021-03-12
    Publishing country England
    Document type Clinical Trial, Phase II ; Journal Article
    ZDB-ID 2115647-5
    ISSN 1349-7006 ; 1349-7006
    ISSN (online) 1349-7006
    ISSN 1349-7006
    DOI 10.1111/cas.14811
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Identification of a Biomarker Combination for Survival Stratification in pStage II/III Gastric Cancer after Curative Resection.

    Hashimoto, Itaru / Kimura, Yayoi / Oue, Naohide / Hiroshima, Yukihiko / Aoyama, Toru / Rino, Yasushi / Yokose, Tomoyuki / Yasui, Wataru / Miyagi, Yohei / Oshima, Takashi

    Cancers

    2022  Volume 14, Issue 18

    Abstract: Background: We sought to identify an optimal combination of survival risk stratification markers in patients with pathological (p) stage II/III gastric cancer (GC) after curative resection.: Methods: We measured the expression levels of 127 genes in ... ...

    Abstract Background: We sought to identify an optimal combination of survival risk stratification markers in patients with pathological (p) stage II/III gastric cancer (GC) after curative resection.
    Methods: We measured the expression levels of 127 genes in pStage II/III GC tissues of two patient cohorts by quantitative polymerase chain reaction (qPCR) and the expression of 1756 proteins between two prognosis (good and poor) groups by proteomic analysis to identify candidate survival stratification markers. Further, immunohistochemistry (IHC) using tumor microarrays (TMAs) in another cohort of patients was performed to identify an optimal biomarker combination for survival stratification in GC patients.
    Results: secreted protein acidic and rich in cysteine (SPARC), erb-b2 receptor tyrosine kinase 2 (ERBB2), inhibin subunit beta A (INHBA), matrix metallopeptidase-11 (MMP11), tumor protein p53 (TP53), and platelet-derived growth factor receptor-beta (PDGFRB) were identified as candidate biomarkers from qPCR analysis, and SPARC and galectin-10 were obtained from the proteomic analysis. The combination of PDGFRB, INHBA, MMP11, and galectin-10 was identified as the optimal combination of survival risk stratification markers.
    Conclusions: A combination of four proteins in GC tissues may serve as useful survival risk stratification markers in patients with pStage II/III GC following curative resection. Our results may facilitate future multicenter prospective clinical trials.
    Language English
    Publishing date 2022-09-12
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14184427
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: CRMP4 Up-regulates M2 Macrophages and Myeloid-derived Suppressor Cells to Promote Pancreatic Cancer in Mice.

    Minegishi, Yuzo / Hiroshima, Yukihiko / Yazawa, Keiichi / Sato, Sho / Yabushita, Yasuhiro / Homma, Yuki / Matsuyama, Ryusei / Kato, Ikuma / Goshima, Yoshio / Endo, Itaru

    Anticancer research

    2022  Volume 42, Issue 2, Page(s) 791–799

    Abstract: Background/aim: We previously observed higher prevalence of high-grade pancreatic intraepithelial neoplasia (PanIN) in LSL-Kras: Materials and methods: PanIN was induced by intraperitoneal injection of caerulein into KC-Crmp4: Results: High-grade ... ...

    Abstract Background/aim: We previously observed higher prevalence of high-grade pancreatic intraepithelial neoplasia (PanIN) in LSL-Kras
    Materials and methods: PanIN was induced by intraperitoneal injection of caerulein into KC-Crmp4
    Results: High-grade PanIN in KC mice showed statistically significantly high expression of CD163 (p=0.031) and CD11b (p=0.027). Following subcutaneous injection of Pan02 cells, tumor diameter was greater in Crmp4
    Conclusion: CRMP4 might promote pancreatic cancer by up-regulating M2 macrophages and myeloid-derived suppressor cells.
    MeSH term(s) Animals ; Antigens, CD/metabolism ; Antigens, Differentiation, Myelomonocytic/metabolism ; CD11b Antigen/metabolism ; Cell Line, Tumor ; Disease Models, Animal ; Macrophages/metabolism ; Mice ; Myeloid-Derived Suppressor Cells/metabolism ; Nerve Tissue Proteins/deficiency ; Nerve Tissue Proteins/metabolism ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Precancerous Conditions/immunology ; Precancerous Conditions/metabolism ; Precancerous Conditions/pathology ; Receptors, Cell Surface/metabolism ; Tumor Burden
    Chemical Substances Antigens, CD ; Antigens, Differentiation, Myelomonocytic ; CD11b Antigen ; CD163 antigen ; Dpysl3 protein, mouse ; Itgam protein, mouse ; Nerve Tissue Proteins ; Receptors, Cell Surface
    Language English
    Publishing date 2022-01-29
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.15537
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Asialoglycoprotein Receptor 2 Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection.

    Oshima, Takashi / Hashimoto, Itaru / Hiroshima, Yukihiko / Kimura, Yayoi / Tanabe, Mie / Onuma, Shizune / Nagasawa, Shinsuke / Kanematsu, Kyohei / Aoyama, Toru / Yamada, Takanobu / Ogata, Takashi / Rino, Yasushi / Saito, Aya / Miyagi, Yohei

    Anticancer research

    2023  Volume 44, Issue 1, Page(s) 397–402

    Abstract: Background/aim: The asialoglycoprotein receptor 2 gene (ASGR2) encodes a subunit of the asialoglycoprotein receptor, a transmembrane protein, which has recently been reported to be involved in gastric cancer (GC) progression. This study aimed to ... ...

    Abstract Background/aim: The asialoglycoprotein receptor 2 gene (ASGR2) encodes a subunit of the asialoglycoprotein receptor, a transmembrane protein, which has recently been reported to be involved in gastric cancer (GC) progression. This study aimed to investigate the clinical significance of ASGR2 expression in GC tissues of patients with locally advanced gastric cancer (LAGC) after curative resection.
    Patients and methods: ASGR2 expression was measured in GC tissues and adjacent normal gastric mucosa in 253 patients with pStage II/III GC who underwent curative resection, by using quantitative polymerase chain reaction. We compared the expression levels in GC tissues and adjacent normal stomach mucosa, and evaluated the relationship of its expression in GC tissues with clinicopathological factors and overall survival (OS).
    Results: ASGR2 expression was significantly associated with lymph node metastasis and venous invasion. The high ASGR2-expression group demonstrated significantly lower survival than the low expression group (5-year survival 55.5% vs. 72.6%; p=0.009). Furthermore, in multivariate analysis, high ASGR2 expression was an independent factor for poor OS (hazard ratio=2.030; 95% confidence interval=1.318-3.127; p=0.001).
    Conclusion: ASGR2 expression in GC tissues may be a useful prognostic marker in patients with LAGC after curative resection.
    MeSH term(s) Humans ; Stomach Neoplasms/genetics ; Stomach Neoplasms/surgery ; Stomach Neoplasms/pathology ; Asialoglycoprotein Receptor ; Prognosis ; Lymphatic Metastasis ; Neoplasm Staging
    Chemical Substances Asialoglycoprotein Receptor
    Language English
    Publishing date 2023-12-30
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.16824
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Clinical Significance of Chitinase-3-like Protein 1 Gene Expression in Patients With Locally Advanced Gastric Cancer.

    Oshima, Takashi / Hashimoto, Itaru / Hiroshima, Yukihiko / Kimura, Yayoi / Tanabe, Mie / Onuma, Shizune / Nagasawa, Shinsuke / Kanematsu, Kyohei / Aoyama, Toru / Yamada, Takanobu / Ogata, Takashi / Rino, Yasushi / Saito, Aya / Miyagi, Yohei

    Anticancer research

    2023  Volume 44, Issue 1, Page(s) 307–312

    Abstract: Background/aim: Chitinase-3-like protein 1 (CHI3L1), encoded by CHI3L1, is thought to be involved in growth, invasion, migration, and resistance to chemotherapy in cancer. This study aimed to investigate the clinical significance of CHI3L1 expression as ...

    Abstract Background/aim: Chitinase-3-like protein 1 (CHI3L1), encoded by CHI3L1, is thought to be involved in growth, invasion, migration, and resistance to chemotherapy in cancer. This study aimed to investigate the clinical significance of CHI3L1 expression as a biomarker in gastric cancer (GC) tissues of patients with locally advanced GC after curative resection.
    Patients and methods: Quantitative polymerase chain reaction (PCR) was used to determined CHI3L1 expression in GC tissues and adjacent normal gastric mucosa of 253 patients with pStage II/III GC who underwent curative resection. We compared the expression levels in GC tissues and adjacent normal gastric mucosa, and examined the relationship between expression in GC tissues and clinicopathological factors and overall survival (OS) in these patients.
    Results: CHI3L1 expression was significantly associated with lymph-node metastasis and venous invasion. OS rate was significantly lower in the high- than in the low-CHI3L1 expression group (5-year survival 55.5% vs. 72.6%; p=0.009). Furthermore, in multivariate analysis, high CHI3L1 gene expression was an independent factor for poor OS (hazard ratio=2.030; 95% confidence interval=1.318-3.127; p=0.001).
    Conclusion: In patients with locally advanced GC after curative resection, expression of the CHI3L1 in GC tissue may be a useful prognostic marker.
    MeSH term(s) Humans ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Chitinase-3-Like Protein 1/genetics ; Clinical Relevance ; Gene Expression ; Neoplasm Staging ; Prognosis ; Stomach Neoplasms/genetics ; Stomach Neoplasms/surgery ; Stomach Neoplasms/metabolism
    Chemical Substances Biomarkers, Tumor ; Chitinase-3-Like Protein 1 ; CHI3L1 protein, human
    Language English
    Publishing date 2023-12-28
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.16813
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Clinical Significance of Pregnancy Zone Protein Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection.

    Oshima, Takashi / Hashimoto, Itaru / Hiroshima, Yukihiko / Kimura, Yayoi / Tanabe, Mie / Onuma, Shizune / Morita, Junya / Nagasawa, Shinsuke / Kanematsu, Kyohei / Aoyama, Toru / Yamada, Takanobu / Ogata, Takashi / Rino, Yasushi / Saito, Aya / Miyagi, Yohei

    Anticancer research

    2023  Volume 44, Issue 1, Page(s) 369–374

    Abstract: Background/aim: Pregnancy zone protein (PZP), encoded by PZP, belongs to the α-2-macroglobulin superfamily, and plays an important role in inflammatory responses and immune cell activation in cancer. However, the relationship between gastric cancer (GC) ...

    Abstract Background/aim: Pregnancy zone protein (PZP), encoded by PZP, belongs to the α-2-macroglobulin superfamily, and plays an important role in inflammatory responses and immune cell activation in cancer. However, the relationship between gastric cancer (GC) and PZP is poorly studied. This study investigated the clinical significance of PZP expression in GC tissues of patients with locally advanced GC after curative resection.
    Patients and methods: Using quantitative polymerase chain reaction, we measured PZP expression in GC tissues and adjacent normal gastric mucosa of 253 patients with pStage II/III GC who underwent curative resection. We compared the expression levels of PZP in GC tissues and adjacent normal gastric mucosa and examined the relationship of PZP expression in GC tissues with clinicopathological factors and overall survival (OS).
    Results: PZP expression was significantly associated with histology, venous invasion, and pathological stage. The high PZP expression group had significantly worse OS than did the low expression group (5-year survival 48.6% vs. 68.5%, p=0.0003). Furthermore, in multivariate analysis, high PZP expression was an independent factor for poor OS (hazard ratio=1.984, 95% confidence interval=1.307-3.012, p=0.0013).
    Conclusion: In post-curative resection patients with locally advanced GC, PZP expression in GC tissue may be a useful prognostic marker.
    MeSH term(s) Humans ; Clinical Relevance ; Gastrectomy ; Prognosis ; Stomach Neoplasms/pathology ; Pregnancy Proteins/genetics
    Chemical Substances PZP protein, human ; Pregnancy Proteins
    Language English
    Publishing date 2023-12-31
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.16820
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top